Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer

US7642342B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Pia M. Challita-Eid · Calabasas, US
• Arthur B. Raitano · Los Angeles, US
• Mary Faris · Los Angeles, US
• Rene S. Hubert · Los Angeles, US
• Karen Jane Meyrick Morrison · Santa Monica, US
• Robert Kendall Morrison · Santa Monica, US
• Wangmao Ge · Tampa, US
• Aya Jakobovits · Beverly Hills, US

Key dates

• Filing date: May 26, 2006
• Grant date: Jan 5, 2010
• Expiry date: Jun 8, 2027

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T436/143333
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table 1. Consequently, 161P5C5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P5C5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P5C5 can be used in active or passive immunization.